Detalhe da pesquisa
1.
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Oncology
; 102(4): 318-326, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-37778345
2.
Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
BMC Cancer
; 22(1): 1228, 2022 Nov 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36443704
3.
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Oncologist
; 25(8): 702-711, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32386255
4.
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.
J Formos Med Assoc
; 117(4): 326-331, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28499641
5.
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
Curr Oncol Rep
; 19(1): 4, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-28138934
6.
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
J Biomed Sci
; 23(1): 86, 2016 Dec 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27912760
7.
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Curr Opin Oncol
; 27(2): 94-101, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25611025
8.
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Nat Commun
; 14(1): 2781, 2023 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37188668
9.
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
Cancers (Basel)
; 15(20)2023 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37894366
10.
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
Clin Cancer Res
; 28(8): 1560-1571, 2022 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35046059
11.
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
Anticancer Res
; 41(3): 1231-1242, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33788714
12.
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC.
JTO Clin Res Rep
; 2(1): 100099, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34589970
13.
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol
; 15(1): 50-61, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31557536
14.
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Eur J Cancer
; 124: 110-122, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31760310
15.
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.
Ther Adv Med Oncol
; 11: 1758835919890286, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31803256
16.
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Expert Opin Pharmacother
; 19(8): 851-864, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29726292
17.
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
J Cancer
; 9(10): 1813-1820, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29805708
18.
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Lung Cancer
; 110: 7-13, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28676222
19.
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis.
Med Oncol
; 34(8): 143, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28726044
20.
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
J Thorac Oncol
; 16(9): 1426-1428, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34425993